References
- Gjorup IE, Smith E, Borgwardt L, Skinhoj P. 20-y survey of the epidemiology of hepatitis B in Denmark: effect of immigration. Scand J Infect Dis 2003; 35: 260–4
- Weis NM, Christensen PB, Laursen AL. Treatment of chronic hepatitis C. The Danish Society of Infection Medicine. Ugeskr Laeger 2006; 168: 1221
- Puoti C, Guido M, Mangia A, Persico M, Prati D. Clinical management of HCV carriers with normal aminotransferase levels. Dig Liver Dis 2003; 35: 362–9
- NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statement 2002; 19: 1–46
- Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut 2003; 52: 1784–7
- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289–93
- Zheng M, Cai WM, Weng HL, Liu RH. ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis. World J Gastroenterol 2002; 8: 1073–6
- Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147–71
- Gronbaek K, Christensen PB, Hamilton-Dutoit S, Federspiel BH, Hage E, Jensen OJ, et al. Inter-observer variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J Viral Hepat 2002; 9: 443–9
- Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825–32
- Hollander A, Glaumann H, Weiland O. Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre. Scand J Gastroenterol 2004; 39: 164–7
- Gronbaek K, Krarup HB, Moller H, Krogsgaard K, Franzmann M, Sonne J, et al. Natural history and aetiology of liver disease in patients with previous community-acquired acute non-A, non-B hepatitis. A follow-up study of 178 Danish patients consecutively enrolled in The Copenhagen Hepatitis Acuta Programme in the period 1969–1987. J Hepatol 1999; 31: 800–7
- Seeff LB. Natural history of hepatitis C. Hepatology 1997; 26(Suppl 1)S21–8
- Afdhal NH. The natural history of hepatitis C. Semin Liver Dis 2004; 24(Suppl 2)3–8
- Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36(Suppl 1)S47–56
- Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2419–25
- Mathurin P, Moussalli J, Cadranel JF, Thibault V, Charlotte F, Dumouchel P, et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998; 27: 868–72
- Nutt AK, Hassan HA, Lindsey J, Lamps LW, Raufman JP. Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels. Am J Med 2000; 109: 62–4
- Pradat P, Alberti A, Poynard T, Esteban JI, Weiland O, Marcellin P, et al. Predictive value of ALT levels for histological findings in chronic hepatitis C: a European collaborative study. Hepatology 2002; 36: 973–7
- Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P, et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997; 26: 1393–8